Genentech has announced FDA approval for Lucentis® as a treatment for patients with choroidal neovascularization (CNV) resulting from myopic macular degeneration (MMD), also known as myopic degeneration. Severe myopia (near-sightedness) can cause uncorrectable central vision impairment, and it may advance to total central vision loss from CNV, which is growth and leakage of blood vessels [Read More]
Author: droberts
Photobiomodulation—A New Treatment For Dry AMD?
(Updated 11/8/17) A new non-invasive technology from LumiThera Inc. may help improve vision in people with dry age-related macular degeneration. Photobiomodulation involves exposure of the retina to light from diodes emitting red, yellow, and infrared wavelengths. Researchers in Switzerland and Toronto recently found that treating eyes three times a week for three weeks improved best [Read More]
Eye Drops for Wet AMD Showing Positive Results
Eye drops continue to show promise as future treatments for wet AMD and other eye diseases involving blood vessel growth and hemorrhaging in the retina. In a presentation at the 2015 Ophthalmology Innovation Summit at the American Academy of Ophthalmology. Paul G. Chaney (President and CEO of Panoptica) reported preliminary results from the PAN-90806 clinical [Read More]
NHTSA sets 'Quiet Car' safety standard
New requirement of audible alert will help prevent 2,400 pedestrian injuries a year The U.S. Department of Transportation’s National Highway Traffic Safety Administration (NHTSA) is adding a sound requirement for all newly manufactured hybrid and electric light-duty vehicles to help protect pedestrians. The new federal safety standard will help pedestrians who are blind, have low vision, and [Read More]
FDA Grants Priority Review for Myopic CNV Treatment
Genentech, makers of Lucentis® (ranibizumab injection) for wet AMD, has been approved for Priority Review by the FDA to study Lucentis for the treatment of myopic choroidal neovascularization (mCNV). Also known as degenerative myopia, mCNV is a complication of severe near-sightedness that can lead to uncorrectable visual impairment. The FDA’s approval is based on results from the Phase [Read More]